H2020Индивидуална стипендия2020–2022

TyphiNET · A global multi-institutional Typhoid fever genomic surveillance network to improve global public health outcomes

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2020-04-01 → 2022-03-31
Финансиране от ЕС: 212 934 €
Участници: 1
Схема: MSCA-IF-EF-ST

Линиите свързват координатора с партньорите.

Накратко на български

Генетичният профил на бактерията Salmonella Typhi се проследява, за да се разбере как се разпространява устойчивостта към антибиотици между различните държави. Това помага за по-точния избор на лекарства и по-ефективното ограничаване на тифоза в световен мащаб.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

A global multi-institutional Typhoid fever genomic surveillance network to improve global public health outcomes

Globally there are ~10 million typhoid fever cases per year, resulting in >100,000 deaths from infection with the causative agent, Salmonella Typhi (Typhi). Antimicrobial therapy is the mainstay of typhoid fever control, and genomic epidemiology studies have revealed that drug resistance emerging in one country can rapidly spread to other neighbouring countries and intercontinentally. Genomic and phenotypic surveillance for typhoid and antimicrobial resistance (AMR) is therefore very important for disease control. TyphiNET aimed to develop innovative approaches for typhoid genomic surveillance through three main objectives: (1) to unlock data from travel-associated typhoid cases in high income countries that are adopting genomics for routine Salmonella surveillance; (2) to unlock data from project-based genomic surveillance in endemic areas; and (3) to develop an open access publicly available platform for synergising, visualising, and disseminating large scale genomic data sourced from sentinel and endemic area surveillance. TyphiNET outcomes are informative for the management of both endemic disease in low- and middle-income countries and travel-associated cases elsewhere, including providing region- and country-specific data to inform empirical antimicrobial choice and strategic targeting of control and intervention strategies.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Globally there are ~20 million typhoid fever cases per year, resulting in ~200,000 deaths from infection with the causative agent, Salmonella Typhi. Antimicrobial therapy is the mainstay of typhoid fever control, and genomic epidemiology studies have revealed that drug resistance emerging in one country can rapidly spread to other neighbouring countries and intercontinentally. Genomic and phenotypic surveillance for typhoid and antimicrobial resistance (AMR) is therefore very important for disease control. TyphiNET aims to develop innovative approaches to bring the benefits of typhoid genomic surveillance to LMICs where the disease is endemic through three main goals: (1) to unlock data from travel-associated typhoid cases in high income countries that are adopting genomics for routine Salmonella surveillance (2) to unlock data from project-based genomic surveillance in endemic areas (beginning with five key collaborative projects across Asia and Africa) and (3) develop an open access publicly available platform for synergising, visualising, and disseminating large scale genomic data sourced from sentinel and endemic area surveillance. Research questions will include inferring genomic epidemiology parameters (prevalence of strain types, resistance to specific antimicrobials, and regional transmission patterns) for different countries/regions using data from sentinel surveillance and from endemic area surveillance; comparison of these to demonstrate the utility of sentinel traveller surveillance for predicting endemic area disease patterns; and comparison of disease dynamics between regions. Outcomes will inform management of both endemic disease in LMICs and travel-associated cases elsewhere, including providing region- and country-specific data to inform empirical antimicrobial choice; and will reveal coverage gaps in endemic area surveillance to be targeted in future studies.

Оригинален текст от CORDIS (на английски).

Участници

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER · LondonКоординаторОбединеното кралство